---
figid: PMC3120937__WJG-17-2781-g002
figtitle: Drug inhibition of signalling pathways
organisms:
- NA
pmcid: PMC3120937
filename: WJG-17-2781-g002.jpg
figlink: /pmc/articles/PMC3120937/figure/F2/
number: F2
caption: Drug inhibition of signalling pathways. Drugs that target signalling pathways
  can be divided into two groups. Antibodies [Becazutumab, trastuzumab, cetuximab
  and matuzumab are antibodies that target the receptor tyrosine kinase (RTK), vascular
  epidermal growth factor receptor (VEGFR), human epidermal growth factor receptor
  2 (HER2) and epidermal growth factor receptor 1 (EGFR) respectively] and small molecular
  inhibitors (The small molecular inhibitors gefitinib and erlotinib target EGFR.
  Temsirolimus specifically inhibits the PI3-kinase pathway at the level of Raptor/mTOR.
  CI1040 and PD0325901 inhibits ERK MAP kinase pathway at the level of MEK. Sorafenib
  is a dual inhibitor of the VEGF receptor and ERK MAP kinase at the level of RAF).
papertitle: 'Targeting key signalling pathways in oesophageal adenocarcinoma: A reality
  for personalised medicine?.'
reftext: Richard R Keld, et al. World J Gastroenterol. 2011 Jun 21;17(23):2781-2790.
year: '2011'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9506567
figid_alias: PMC3120937__F2
figtype: Figure
organisms_ner:
- Drosophila melanogaster
redirect_from: /figures/PMC3120937__F2
ndex: 338eb953-dee5-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3120937__WJG-17-2781-g002.html
  '@type': Dataset
  description: Drug inhibition of signalling pathways. Drugs that target signalling
    pathways can be divided into two groups. Antibodies [Becazutumab, trastuzumab,
    cetuximab and matuzumab are antibodies that target the receptor tyrosine kinase
    (RTK), vascular epidermal growth factor receptor (VEGFR), human epidermal growth
    factor receptor 2 (HER2) and epidermal growth factor receptor 1 (EGFR) respectively]
    and small molecular inhibitors (The small molecular inhibitors gefitinib and erlotinib
    target EGFR. Temsirolimus specifically inhibits the PI3-kinase pathway at the
    level of Raptor/mTOR. CI1040 and PD0325901 inhibits ERK MAP kinase pathway at
    the level of MEK. Sorafenib is a dual inhibitor of the VEGF receptor and ERK MAP
    kinase at the level of RAF).
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Pvr
  - Egfr
  - MKP-4
  - p38b
  - rl
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Wnt5
  - Wnt4
  - wg
  - Wnt2
  - raptor
  - Mtor
  - Tor
  - Raf
  - Dsor1
  - Mtk
  - Temsirolimus
  - PD0325901
  - Cancer
  - Lung cancer
---
